Oncocyte(OCX) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 ● Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phase ● FDA pre-submission process for approval of kitted clinical test is underway IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX) ("Oncocyte" or the "Company"), a diagnostics tech ...